Egetis Therapeutics Logo

Egetis Therapeutics

Develops and commercializes treatments for serious and rare diseases.

EGTX | ST

Overview

Corporate Details

ISIN(s):
SE0003815604
LEI:
549300RZCKGWRUBPMY22
Country:
Sweden
Address:
Klara Norra Kyrkogata 26, 111 22 Stockholm

Description

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-10-05 08:01
PledPharma genomför en fullt garanterad företrädesemission om cirka 200 MSEK me…
Swedish 101.2 KB
2020-08-20 08:00 Swedish 302.0 KB
2020-08-20 08:00 English 299.0 KB
2020-07-30 08:00
Changes in PledPharma’s Board of Directors and committees
English 126.4 KB
2020-07-30 08:00
PledPharma meddelar förändring av styrelsen och utskott
Swedish 126.8 KB
2020-06-27 10:20 English 34.1 KB
2020-06-24 08:00
PledPharma utser Marie-Louise Alamaa som tillförordnad CFO
Swedish 127.2 KB
2020-06-24 08:00
Marie-Louise Alamaa appointed interim CFO at PledPharma
English 146.5 KB
2020-05-26 08:30
CFO Yilmaz Mahshid lämnar PledPharma
Swedish 139.8 KB
2020-05-26 08:30
CFO Yilmaz Mahshid leaves PledPharma
English 146.4 KB
2020-04-23 17:35
Kommuniké från årsstämman i PledPharma AB (publ)
Swedish 99.0 KB
2020-04-23 17:35
Kommuniké från årsstämman i PledPharma AB (publ)
Swedish 99.0 KB
2020-04-22 08:00 Swedish 290.0 KB
2020-04-22 08:00 English 293.6 KB
2020-04-06 08:30
PledPharma to close POLAR phase 3 program in the third quarter
English 162.2 KB

Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Egetis Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-09 Yilmaz Mahshid Other Sell 39,753 268,332.75 SEK
2025-01-08 Yilmaz Mahshid Other Sell 98,567 653,499.21 SEK
2025-01-07 Yilmaz Mahshid Other Sell 74,769 507,681.51 SEK
2024-10-07 Nicklas Westerholm Other Buy 10,142 43,103.50 SEK
2024-10-07 Yilmaz Mahshid Other Buy 10,000 42,250.00 SEK
2023-07-07 Henrik Krook Other Buy 33,594 133,704.12 SEK
2023-07-06 Christian Sonesson Other Buy 3,616 14,391.68 SEK
2023-07-06 Christian Sonesson Other Buy 2,000 7,920.00 SEK
2023-07-05 Christian Sonesson Other Buy 1,384 5,452.96 SEK
2023-07-04 Nicklas Westerholm Other Buy 15,350 60,632.50 SEK

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
A biopharmaceutical company developing RNA interference (RNAi) therapeutics.
United States of America
ALNY
Alpha Cognition Inc. Logo
A biopharmaceutical company developing treatments for neurodegenerative diseases.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufacturer of critical reagents for the life sciences industry.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
A clinical-stage biotech developing novel treatments for neurodegenerative diseases.
United States of America
ATHE
Altimmune, Inc. Logo
Clinical-stage biopharma developing peptide therapeutics for obesity and liver diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Develops precision medicines for neuropsychiatric conditions using patient biology.
United States of America
ANRO
ALUMIS INC. Logo
Clinical-stage biopharma developing precision medicines for autoimmune diseases.
United States of America
ALMS
Alvotech Holdings S.A Logo
A biotechnology company developing and manufacturing biosimilar medicines worldwide.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage immuno-oncology company developing therapies to combat cancer.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Develops treatments for neurodegenerative diseases and psychiatric disorders.
United States of America
ALZN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.